Dhampur Bio Organics Limited has signed a 10-year technology licensing agreement with Switzerland's Planetary SA to produce mycoprotein in India. The move marks a strategic shift for the sugar-based manufacturer, as it utilizes molasses as feedstock to enter the higher-margin alternative protein sector. DBO will handle infrastructure setup while paying a 10% royalty on after-tax revenue to Planetary SA, with long-term plans to form a joint venture.
Dhampur Bio Organics Enters Mycoprotein Market
Dhampur Bio Organics Limited (DBO) has executed a 10-year technology licensing agreement with Switzerland-based Planetary SA to manufacture mycoprotein in India. The deal follows a previously announced non-binding term sheet and sets the framework for a new, high-margin revenue stream for the company.
Reader Takeaway: Diversification into high-value protein production offers growth, but success depends on specialized infrastructure execution and cost management.
What just happened
DBO and Planetary SA have formalized a collaboration where DBO will act as the manufacturer, utilizing its existing sugar and molasses feedstock to produce mycoprotein. Planetary SA will provide the proprietary technology, engineering support, and serve as the product off-taker. The agreement includes a commitment to eventually form a joint venture to handle commercialization in India.
Why this matters
The project allows DBO to move downstream in its value chain, transitioning from a commodity-focused sugar manufacturer to a player in the specialized food-tech sector. Management expects this vertical integration to yield higher profitability than traditional operations by capitalizing on the synergy between sugar production and mycoprotein fermentation.
Financial Obligations
Under the terms, DBO will pay a 10% royalty on after-tax revenue to Planetary SA on a quarterly basis. The company is also responsible for all upfront capital requirements, including engineering, installation, and commissioning costs, as well as one-time IT platform setup fees.
Risks to watch
Execution risk remains the primary hurdle, as DBO must build and commission specialized, complex infrastructure for the first time. Furthermore, shareholders should monitor how the initial capital expenditure for the launch and the ongoing royalty payments affect the company’s operating margins during the project's early phases.
What to track next
Investors should look for updates regarding the construction timeline of the dedicated infrastructure and future disclosures regarding the formation of the planned joint venture.